Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

45.1 x 31.8 cm. (17.8 x 12.5 in.) ...

Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 349.85 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...

Prime Minister James Marape has reaffirmed his government’s commitment to strengthening superannuation and voluntary savings for Papua New Guineans, announcing key reforms aimed at ensuring financial ...